Drug Trial Radar · NCT04102150
Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Nov 21, 2019
Primary completion
Apr 24, 2021
Study completion Oct 27, 2024
Sponsor
- Lead sponsor
- Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Sep 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).
Conditions
- Adult T-cell Leukemia/Lymphoma
Interventions
Valemetostat TosylateDrug
Once a day, 200 mg, oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR) assessed by central evaluation organizationTime frame: Through the end of the study (within approximately 5 years)
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Kagoshima University Hospital
Kagoshima, Japan
Nagasaki University Hospital
Nagasaki, Japan
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
Ehime University Hospital
Tōon-shi, Ehime, Japan
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, Fukuoka, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Imamura General Hospital
Kagoshima, Kagoshima-ken, Japan
Kochi Medical School Hospital
Nankoku-shi, Kochi, Japan
Kumamoto University Hospital
Kumamoto, Kumamoto, Japan
National University Corporation Tohoku University Tohoku University Hospital
Sendai, Miyagi, Japan
University of Miyazaki Hospital
Miyazaki, Miyazaki, Japan
Local Incorporated Administrative Agency Sasebo City General Hospital
Sasebo-shi, Nagasaki, Japan
Okayama University Hospital
Okayama, Okayama-ken, Japan
University of the Ryukyus Hospital
Nakagami-gun, Okinawa, Japan
Osaka International Cancer Institute
Osaka, Osaka, Japan
Kindai University Hospital
Osakasayama-shi, Osaka, Japan
Osaka University Hospital
Suita-shi, Osaka, Japan
Saga University Hospital
Saga, Saga-ken, Japan
Saitama Medical University International Medical Center
Hidaka-shi, Saitama, Japan
Hamamatsu University Hospital
Hamamatsu, Shizuoka, Japan
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan
IMSUT Hospital, The Institute of Medical Science, The University of Tokyo
Minato-Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.